⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Zevra Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Zevra Therapeutics
↗Celebration, Florida, USA
Zevra Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and delivering life-changing therapies for patients living with rare diseases. The company focuses on addressing significant unmet medical needs through scientific innovation and a patient-centric approach to drug development and commercialization.
Formerly known as KemPharm, Inc., the company rebranded to Zevra Therapeutics in 2023 to reflect its strategic pivot toward a rare disease-focused portfolio. Zevra's commercial operations are supported by approved products such as MIPLYFFA® and OLPRUVA®, with an active pipeline targeting conditions including Niemann-Pick disease type C (NPC) and Vascular Ehlers-Danlos Syndrome (VEDS).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$100M-$150M
Founded:2007
Ownership:public
Status:operating
FUNDING
Investors:FMR LLC
STOCK
Exchange:NASDAQ
Ticker:ZVRA
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Trial Phases:Phase 3: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Patient advocacy groups (various rare disease organizations)
COMPETITION
Position:Emerging
Competitors:Theravance Biopharma, Elite Pharmaceuticals, CorMedix, Xeris Biopharma Holdings
LEADERSHIP
Key Executives:
Neil F. McFarlane - President and CEO
Justin Renz - Chief Financial Officer
Rahsaan W. Thompson - Chief Legal Officer
Board Members:Corey Watton
LINKS
Website:zevra.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Zevra Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.